Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.6840 +0.0719 (+11.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
News headline image
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Updates Regarding the Status of the AutoMax Merger
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Secures Strategic Advantage with Grant of European Patent
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc to Acquire AutoMax
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments
From SciSparc Ltd
Via GlobeNewswire
News headline image
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.